# Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment

Source: https://onco.cc/trials/nct04739527/  
OnCo record `nct04739527` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Vididencel run by University Medical Center Groningen, completed.

## Summary

Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment is a phase 1 interventional study registered as NCT04739527 by University Medical Center Groningen, with 17 participants enrolled, started 2021-06-10. Conditions recorded: Ovarian Cancer. Interventions recorded: DCP-001.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04739527
- Phase: 1
- Setting: An Open Label, Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment
- Sponsor: University Medical Center Groningen
- Enrolled: 17

## Sources

- ClinicalTrials.gov NCT04739527: https://clinicaltrials.gov/study/NCT04739527

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Vididencel](https://onco.cc/drugs/vididencel/)
- companies: [Mendus](https://onco.cc/companies/mendus/)

---
JSON: https://onco.cc/api/v1/entities/nct04739527.json